Table 17 Summary of findings table for treatment with galcanezumab 120 mg compared with no treatment for prevention of chronic migraine

Reduction of monthly migraine days follow up: 3 months

The mean reduction of monthly headache days was −2.7 days

The mean reduction of monthly headache days in the intervention group was 2.1 days lower (2.9 lower to 1.3 lower)

–

⨁⨁⨁◯MEDIUM^a

Treatment with Galcanezumab 120 mg reduces monthly migraine days slightly compared to placebo.

Reduction of monthly acute treatment days follow up: 3 months

The mean reduction of monthly headache days was −2.2 days

The mean reduction of monthly acute treatment days in the intervention group was 2.5 days lower (3.3 lower to 1.8 lower)^b

–

⨁⨁⨁◯MEDIUM^a

Treatment with Galcanezumab 120 mg reduces monthly acute treatment days slightly compared to placebo.

Improvement in functional MIDAS score follow up: 3 months

The mean improvement in functional MIDAS score was −11.5 points

The mean improvement in functional MIDAS score in the intervention group was 8.7 points lower (16.4 lower to 1.1 lower)

–

⨁⨁⨁◯MEDIUM^a

Treatment with Galcanezumab 120 mg improves functional MIDAS score compared to placebo.

At least 50% reduction of monthly migraine days follow up: 3 months

149 per 1000

284 per 1000(215 to 375)

RR 1.9112(1.4477 to 2.5232)

⨁⨁⨁◯MEDIUM^a

Treatment with Galcanezumab 120 mg mg results in at least 50% reduction of monthly headache days compared to placebo.

Serious adverse events follow up: 3 months

7 per 1000

4 per 1000(0 to 34)

RR 0.5288(0.0594 to 4.7092)

⨁⨁⨁◯MEDIUM^a

Treatment with Galcanezumab 120 mg mg results in a possibly unimportant effect on serious adverse event occurrence compared to placebo.

Mortalityfollow up: 3 months

0 per 1000

0 per 1000(0 to 0)

not estimable

No deaths were observed with treatment with Galcanezumab 120 mg or placebo